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Abstract
Beam Output Auditing (BOA) is one key process of the EORTC radiation therapy quality assurance program. Here the
results obtained between 2005 and 2014 are presented and compared to previous results.
For all BOA reports the following parameters were scored: centre, country, date of audit, beam energies and treatment
machines audited, auditing organisation, percentage of agreement between stated and measured dose.
Four-hundred and sixty-one BOA reports were analyzed containing the results of 1790 photon and 1366 electron
beams, delivered by 755 different treatment machines. The majority of beams (91.1%) were within the optimal limit
of≤ 3%. Only 13 beams (0.4%; n = 9 electrons; n = 4 photons), were out of the range of acceptance of≤ 5%. Previous
reviews reported a much higher percentage of 2.5% or more of the BOAs with >5% deviation.
The majority of EORTC centres present beam output variations within the 3% tolerance cutoff value and only 0.4% of
audited beams presented with variations of more than 5%. This is an important improvement compared to previous
BOA results.
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Introduction
In 1982 the European Organisation for Research and Treat-
ment of Cancer - Radiation Oncology Group (EORTC-
ROG started a quality assurance (QA) program in radiation
therapy (RTQA). ) In 1986 a Beam Output Audit (BOA)
program was incorporated in this RTQA program [1, 2].
This RTQA process is in essence a verification of the dose
delivery under reference conditions at the accruing site and
defines, with the facility questionnaire the RTQA Level 1
[3]. It is a dose measurement performed by a national or
international auditor, independent from the site, and the re-
sults are fed back to EORTC headquarters [4]. Published
BOA data measured by an independent body and collected
in the perspective of a trial coordination organization is
scarce. A description of the method with mailed Thermo-
luminescence dosemeters (TLDs) and the results for the
1987–1989 and 1987–1992 periods have been published
earlier [1, 5]. Themain goal of this paper is to present the
BOA results from 2005 to 2014 stemming from European
and non-European centres participating in EORTC trials.
Materials and methods
There are a number of EORTC-ROG minimum require-
ments that centres should fulfill to get their BOA ap-
proved by the EORTC-ROG [3]. First and foremost, the
audit must be performed independently from the centre,
including at least the highest and lowest photon energy.
The date of measurement should not be longer ago than
2 years at the time a request to participate in a new trial is
received from a centre by the EORTC. Flattened beams
and flattening filter free beams are considered as different
energies. Electron beams are optional, unless the centre
wants to participate in a study with electron treatments.
All measurements need to be preferably within the 3%
agreement, but measurements up to and including 5% are
also accepted [3]. The institutions are notified of the deci-
sion of the EORTC and are alerted if beams are within the
3 to 5% range if applicable. If a site does not fulfil the 5%
tolerance for a single machine or beam the site is not au-
thorized to use that combination of treatment unit type
and energy. The EORTC currently distinguishes 3 treat-
ment unit types: standard linear accelerator, rotational and
robotic. The auditor’s primary standard has to have a clear
traceability back to a national or international primary
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Fig. 1 World-wide distribution and focus on European distribution of centres providing BOA-reports collected and stored at the EORTC. Not taken
into account are the Co60 beams and the ‘stereotactic radiosurgery dosimetry’. The ‘pie-diagrams’ represent the subdivision between the different
levels of acceptance [green: ≤3%; yellow: >3% and≤ 5%; red: >5%]
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standard and the measurements must take place under
standard conditions.
BOA reports capture the following parameters: centre,
country, date of audit, beam energies and treatment ma-
chines audited, auditing organisation and the measured and
stated dose. In addition to the mandatory measurements
under standard conditions, a commercial service provider
(called EQUAL) also reported the measurements they per-
formed on the beam axis under non-standard conditions
(wedged beams, field size 15x20cm, field size 7x7cm, at
SSD of 105, 110 and 115 cm). Additionally, the number of
treatment machines was collected for each centre based
upon the latest EORTC facility questionnaire.
Results
A total of 461 BOA-reports, performed over a time period
of 107 months (February 2005 until December 2013) were
assessed. These reports were made for 279 centres world-
wide, stemming from 33 countries, which provided at least
one BOA-report to EORTC. The results of 3174 beams,
delivered by 755 different treatment units were assessed.
This included 18 results (0.6%) for Co-60 beams, 1790
(56.4%) for photon beams (of which 11 ‘stereotactic radio-
surgery dosimetry’) and 1366 (43.0%) for electron beams.
The world-wide distribution of the centres providing
BOA-reports and the subdivision for each region by ac-
ceptance level is shown in Fig. 1. Not presented in the fig-
ure of Europe are Luxembourg, Slovakia, Lithuania,
Norway, Denmark, Portugal, Cyprus and Ireland, which
each have one BOA-report and were all within the optimal
level of acceptance, except Ireland and Lithuania, which
had a report within the limit of 5% and Portugal, which
had a report out of the limit of 5%. The majority (64%) of
centres submitted 1 BOA report. Forty-four centres (16%)
submitted a BOA-report twice and 55 (20%) more than
twice over the 9-year study period.
Most of the audits were performed by EQUAL. Most
other different auditing bodies can be brought back to the
common denominator of national organizations.
For all but 4 (1.4%) centres, the number of treatment
units at the radiation therapy centre could be retrieved.
The number of treatment units present at a centre ranged
from 1 to 17, with a median of 4. Ten institutions provided
reports which did not fulfill the EORTC requirements.
Therefore, the following results will include the valid 451
BOA reports, excluding the 18 Co-60 beams, of which 17
were within the optimal 3% limit and 1 between 3 and 5%.
The results are summarized in Table 1.
During an audit, the median number of beams tested was
4 (range: 1–65) (Fig. 3), the median number of treatment
units was 2 (range: 1–17) (Fig. 2) and the median number
of beams tested per treatment unit was 2.8 (range: 1 – 9).
The median of the ratio of the number of machines tested
and number of machines in the centre was 0.4 (range: 0.08-
1). Thirteen beams (0.4%; n = 9, electrons; n = 4, photons)
were out of the range of acceptance of 5%, 225 beams
(8.5%; 129 electrons and 96 photons) were within the non-
optimal range of acceptance (3-5%) and 2895 (91.1%; 1225
electrons and 1670 photons) were within the optimal limit
of ≤ 3%. An absolute average difference between stated and
measured dose of 1.35% for photons (SD: 0.99) and 1.55%
for electrons (SD: 1.16) could be seen. The average ratio of
the measured dose and stated dose (Dm/Ds) was 1.00 for
photons and 0.99 for electrons (Figs. 3 and 4). The 13 un-
acceptable beams were from ten BOA-reports, coming
from 8 centres.
Out of 269 centres, 180 (66.9%) had all beams within
the optimal acceptance level (≤3%) and 81 (30.1%) had at
least one beam result within the non-optimal level, but
none out of the range of acceptance. One might expect
that larger centres, having more experience in beam
commissioning and beam QA, would have better BOA re-
sults than smaller centres. However, no association was
observed between the BOA results and the number of
treatment units at a centre. (Fig. 5). In addition, no associ-
ation could be seen with the audit year (Fig. 6). For the
centres, which provided more than one BOA-report, the
evolution over time was checked and no clear improve-
ment of the results over the reported time period for the
different centres was seen.
Table 1 Summary of all beam results
Cutoff level Photon beams (%) Electron beams (%) Co-60
beams
<3% 1670 (94.4%) 1225 (89.9%) 17
3–5% 96 (5.4%) 129 (9.5%) 1
>5% 4 (0.2%) 9 (0.7%)
Total (451 BOA
reports)
1770 (100%) 1363 (100%) 18
Fig. 2 Number of beams per audit, subdivided between the different
levels of acceptance [green: ≤3%; yellow: >3% and≤ 5%; red: >5%]
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The reports of the audits conducted by EQUAL also
contained measurements in non-standard conditions. At
the 3% cutoff level, the pass-rates were for photons
92.2% (standard) vs 93.7% (non-standard) (p = 0.35, chi-
square test of 2 proportions) and for electrons 87.4%
(standard) vs 84.8% (non-standard) (p = 0.39). No com-
parison for these pass-rates were made at the 5% cutoff
level as they contained too few results. Overall, 6.5% of
the photon beams measured by EQUAL were between
3–5 and 0.1% above 5%. More details about the photon
beam results from the EQUAL measurements can be
found in Table 2.
Discussion
When comparing the current results with earlier reported
results an important difference can be seen. An evaluation
over a time period of 6 years (1987–1992), auditing 55 insti-
tutes showed 2.5% of the beams with a higher discrepancy
than 7% between stated and measured dose [1]. The 1998
EQUAL program, auditing 102 centres, noted a rate of 3%
of the photon beam outputs in reference conditions show-
ing deviations outside the acceptance level of 5% [6] and
the IAEA 1998–2001 postal results for 526 photon and 791
Co-60 beams revealed 16% of the beams having a discrep-
ancy outside the 5% limit and even 1.3% (17 beams) with a
discrepancy of more than 20%, with, in general, worse re-
sults for the Co-60 beams than for the photon beams [7].
Other old reports stemming from over 10 to 23 years ago
also reported significant discrepancies [8–11]. Dutreix and
co-workers found 37 out of 125 beams outside the 3% opti-
mal level and observed that 16 out of 22 beams with devia-
tions between 3 to 6% and all 15 beams with a deviation of
more than 6% were from centres not participating in BOAs
within the previous 5 years (8). Izewska and Andreo ob-
served that Only 65% of those hospitals who received TLDs
for the first time had results within the acceptance limits,
while more than 80% of the users that had benefitted from
a previous TLD audit were successful [9].
In the current results, covering reports coming through-
out a much wider part of the world, only 0.2% of the
photon beams were found to be higher than the acceptance
level.
Another feasibility study by the European-Commission
Network verifying mailed dosimetry for electron beams
was initiated in the late nineties. In total 300 (91.5%) out
of 328 beams were found to be within the tolerance level
of 5% [12]. Currently only 0.7% of all the electron beams
were found to be out of this range.
Overall good results could also be seen for the mea-
surements in non-standard conditions. The percentage
Fig. 3 Number of treatment units per audit, subdivided between the different levels of acceptance [green: ≤3%; yellow: >3% and≤ 5%; red: >5%]
Fig. 4 Presentation of all beam-results, with a subdivision in photon- and electron beams. The colors differentiate between the levels of acceptance
[green: ≤3%; yellow: >3% and≤ 5%; red: >5%]
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number of all photon beams – standard and non-
standard conditions - within the non-optimal level of ac-
ceptance from the 1998 EQUAL program are 14% and
those outside of acceptance level are 4%, while the pre-
sented results have 6.5 and 0.1% of the beams in these
categories of acceptance [6].
The difference in our results to those found in litera-
ture might be caused by the presence of a bias, as our
dataset only contains BOA-reports from centres partici-
pating in EORTC lead radiotherapy trials. Additionally,
centres might have provided only a selection of their
BOA data to the EORTC.
More recent publications on RTQA results in trials
suggest that the main sources of protocol deviations are
not due to beam output deviations under reference con-
ditions. Deviations are more likely to be related to am-
biguousness in the trial protocol, delineation variations
and dose calculation and optimization problems in trial
specific treatment plans [13]. Other trial RTQA proce-
dures, which are more and more harmonized globally,
like benchmark exercises, individual case reviews and
complex dosimetry checks are able to detect such proto-
col deviations and nowadays mitigate the need for BOAs
in the context of trial RTQA [4, 14].
It can be defended that omitting the request of a BOA
would make trial RTQA easier, faster and less costly
without loss of RT quality within trials.
Conclusion
Our analysis shows that only 0.2 and 0.7% of all photon
and electron BOA results, respectively, were found dis-
crepant in respect to a 5% cutoff level, which is a substan-
tial improvement compared to previous BOA results.
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Fig. 5 Number of BOA-reports subdivided in the level of acceptance
per number of treatment machines present at a centre. The colors
differentiate between the levels of acceptance [green: ≤3%; yellow:
>3% and≤ 5%; red: >5%]
Fig. 6 Number of BOA-reports, subdivided in level of acceptance
per year of audit. The colors differentiate between the levels of
acceptance [green: ≤3%; yellow: >3% and≤ 5%; red: >5%]
Table 2 Photon beam results from the EQUAL audits for
non-standard conditions
Cutoff
level
Percentage
depth
dose (%)
Beam output
variation open
beams (%)
Beam output
variation wedged
beams (%)
Wedge
transmission
factor
<3% 242 (93%) 462 (93%) 84 (88%) 215 (95%)
3-5% 15 (7%) 29 (5%) 11 (12%) 11 (5%)
>5% 0 (0%) 2 (1%) 0 (0%) 0 (0%)
Total 257 (100%) 493 (100%) 95 (100%) 226 (100%)
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